Your browser doesn't support javascript.
loading
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Rossi, Cédric; Gilhodes, Julia; Maerevoet, Marie; Herbaux, Charles; Morschhauser, Franck; Brice, Pauline; Garciaz, Sylvain; Borel, Cécile; Ysebaert, Loïc; Obéric, Lucie; Lazarovici, Julien; Deau, Bénédicte; Dupuis, Jehan; Chauchet, Adrien; Abraham, Julie; Bijou, Fontanet; Stamatoullas-Bastard, Aspasia; Malfuson, Jean-Valère; Golfier, Camille; Laurent, Camille; Pericart, Sarah; Traverse-Glehen, Alexandra; Kanoun, Salim; Filleron, Thomas; Casasnovas, René-Olivier; Ghesquières, Hervé.
Afiliação
  • Rossi C; Cancer Research Centre of Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.
  • Gilhodes J; Department of Hematology, Dijon University Hospital, Dijon, France.
  • Maerevoet M; Clinical trials office, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France.
  • Herbaux C; Institut Jules Bordet, B 1000 Bruxelles, Belgium.
  • Morschhauser F; Department of Hematology, Unité GRITA, CHRU Claude Huriez, Lille, France.
  • Brice P; Department of Hematology, Unité GRITA, CHRU Claude Huriez, Lille, France.
  • Garciaz S; Department of Hematology, CHU Paris-GH St-Louis Lariboisière F-Widal - Hôpital Saint-Louis, Paris, France.
  • Borel C; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
  • Ysebaert L; Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France.
  • Obéric L; Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France.
  • Lazarovici J; Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France.
  • Deau B; Department of Hematology, Institut Gustave-Roussy, Villejuif, France.
  • Dupuis J; Department of Hematology, CHU Cochin, Paris, France.
  • Chauchet A; Department of Hematology, CHU Henri Mondor, Créteil, France.
  • Abraham J; Department of Hematology, CHU Besançon, Besançon, France.
  • Bijou F; Department of Hematology, CHU Limoges, Limoges, France.
  • Stamatoullas-Bastard A; Department of Hematology, Institut Bergonié, Bordeaux, France.
  • Malfuson JV; Department of Hematology, Centre Henri Becquerel, Rouen, France.
  • Golfier C; Department of Hematology, hôpital d'instruction des armées Percy, Clamart, France.
  • Laurent C; Department of Hematology, Dijon University Hospital, Dijon, France.
  • Pericart S; Anatomy-pathology Department, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France.
  • Traverse-Glehen A; Anatomy-pathology Department, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France.
  • Kanoun S; Anatomy-pathology Department, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
  • Filleron T; Nuclear Medecine Unit, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France.
  • Casasnovas RO; Clinical trials office, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France.
  • Ghesquières H; Department of Hematology, Dijon University Hospital, Dijon, France.
Am J Hematol ; 2018 Jun 08.
Article em En | MEDLINE | ID: mdl-29884994
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Hematol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Hematol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França